Anthera, When IPOs Go Awry (ANTH)
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) is a very unusual Monday IPO. The fact that it is being viewed as a dud has little to do with the day of the week. Late last week,…
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) is a very unusual Monday IPO. The fact that it is being viewed as a dud has little to do with the day of the week. Late last week,…
There are twelve major pharmaceutical firms that dominate this industry worldwide. Their combined market value is over $1 trillion with total annual sales of over $500 billion. The firms have developed and marketed most of the…
The Administration’s ambitious healthcare plan will not make it through Congress. A scaled down version might. The initial broad program had the support of the insurance and drug industries probably due to a calculation that “if you…
The FDA continued is blundering and fumbling as the protector of the American public from big pharma. On the “drugs that kill people but are approved by the FDA” front, two doctors from the…
Humana (NYSE:HUM) will cut 2,500 jobs in one of its business units but add back enough workers in other areas so that the net cut in employees will be 1,400. Humana reported a sharp increase…
Boston Scientific (NYSE:BSX), the worst run of the large medical device and pharma firms based in the US, announced an operating loss for the fourth quarter of 2009 of $1.23 billion. The company’s guidance was…
This past week was filled with many surprises and earnings are still coming on strong. We wanted to look at some companies that either have unfinished business or are on deck with pending news this…
The largest single problem with the budget deficits as the next few years unfold is not the low government receipts due to a poor economy. It is not defence spending or discretionary programs. The really…
More than half of adult Americans used the internet to look up healthcare information in the last year, according to a CDC study conducted in the first six months of last year. The study does not…
Home Diagnostics, Inc. (NASDAQ: HDIX) is this morning’s top pre-market gainer, on news of a buyout. The company has agreed to be acquired by Nipro Corporation for $11.50 per share in a $215 million…
By Douglas A. McIntyre of 24/7 Republican Scott Brown has won the Senate seat held by Ted Kennedy for almost 47 years. Many analysts expect that this will effectively kill the Obama healthcare initiative.…
Med BioGene Inc. has filed for an initial public offering in the United States. Technically this may not be a formal IPO because it trades in Canada where the company is based. We do…
Millions of people in the US contracted the H1N1 flu virus aka swine flu. Almost none of those people died. The WHO and several medical and health organizations in the US believed that H1N1 would be…
Stem cell stocks (tracked in Tickerspy’s Stem Cell Stock’s Index (*RXSTM) are up over 7% today, led by Athersys Inc (NASDAQ: ATHX). Athersys Inc. rose as high as 395% this morning following news that…
Bristol-Myers Squibb Co. (NYSE: BMY) has been a real pest in the world of analyzing options trading activity. There has been a perpetual open interest alert with a monster contract volume in the DEC-2009…